

including whether the information will have practical utility.

(b) Evaluate the accuracy of our estimate of the time and cost burden for this proposed collection, including the validity of the methodology and assumptions used.

(c) Evaluate ways to enhance the quality, utility, and clarity of the information to be collected.

(d) Minimize the reporting burden on those who are to respond, including the use of automated collection techniques or other forms of information technology.

Comments that you submit in response to this notice are a matter of public record. We will include or summarize each comment in our request to OMB to approve this Information Collection Request. Before including your address, phone number, email address, or other personal identifying information in your comment, you should be aware that your entire comment—including your personal identifying information—may be made publicly available at any time. While you may ask us in your comment to withhold your personal identifying information from public review, we cannot guarantee that we will be able to do so.

**Sheleen Dumas,**

*Departmental PRA Compliance Officer, Office of the Under Secretary for Economic Affairs, Commerce Department.*

[FR Doc. 2025–22401 Filed 12–9–25; 8:45 am]

**BILLING CODE 3510–60–P**

## DEPARTMENT OF COMMERCE

### Patent and Trademark Office

[Docket No.: PTO–P–2025–0512]

#### Grant of Interim Extension of the Term of U.S. Patent No. 7,319,099; Bitopertin (GlyT1 inhibitor) Oral Tablets

**AGENCY:** United States Patent and Trademark Office, Commerce.

**ACTION:** Notice of interim patent term extension.

**SUMMARY:** The United States Patent and Trademark Office has issued a certificate under 35 U.S.C. 156(d)(5) for a one-year interim extension of the term of U.S. Patent No. 7,319,099 ('099 patent).

**FOR FURTHER INFORMATION CONTACT:** Ali Salimi, Senior Legal Advisor, Office of Patent Legal Administration, at 571–272–0909 or [ali.salimi@uspto.gov](mailto:ali.salimi@uspto.gov); or Andrea S. Grossman, Legal Advisor, Office of Patent Legal Administration, at (571) 270–3314 or [andrea.grossman@uspto.gov](mailto:andrea.grossman@uspto.gov).

**SUPPLEMENTARY INFORMATION:** 35 U.S.C. 156 generally provides that the term of a patent may be extended for a period of up to five years, if the patent claims a product, or a method of making or using a product, that has been subject to certain defined regulatory review. 35 U.S.C. 156(d)(5) generally provides that the term of such a patent may be extended for no more than five interim periods of up to one year each, if the approval phase of the regulatory review period (RRP) is reasonably expected to extend beyond the expiration date of the patent.

On December 1, 2025, Hoffman-La Roche, Inc., the patent owner of record of the '099 patent, timely filed an application under 35 U.S.C. 156(d)(5) for an interim extension of the term of the '099 patent. The '099 patent claims the human drug product Bitopertin (GlyT1 inhibitor) oral tablets. The application indicates that the approval phase for the regulatory period, as described in 35 U.S.C. 156(g)(1)(B)(ii), for NDA 220707 for the human drug product Bitopertin (GlyT1 inhibitor) oral tablets is ongoing before the Food and Drug Administration for permission to market and use the product commercially.

Review of the patent term extension application indicates that, except for permission to market or use the product commercially, the '099 patent would be eligible for an extension of the patent term under 35 U.S.C. 156, and that the patent should be extended for one year as required by 35 U.S.C. 156(d)(5)(B).

Because it appears reasonable to expect the approval phase of the RRP to continue beyond the expiration date of the patent, *i.e.*, December 17, 2025, interim extension of the '099 patent's term under 35 U.S.C. 156(d)(5) is appropriate.

An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. Patent No. 7,319,099 is granted for a period of one year from the original expiration date of the patent.

**Charles Kim,**

*Deputy Commissioner for Patents, United States Patent and Trademark Office.*

[FR Doc. 2025–22424 Filed 12–9–25; 8:45 am]

**BILLING CODE 3510–16–P**

## CONSUMER FINANCIAL PROTECTION BUREAU

[Docket No. CFPB–2025–0049]

### Agency Information Collection Activities: Comment Request

**AGENCY:** Consumer Financial Protection Bureau.

**ACTION:** Notice and request for comment.

**SUMMARY:** In accordance with the Paperwork Reduction Act of 1995 (PRA), the Consumer Financial Protection Bureau (CFPB or Bureau) is requesting to extend the Office of Management and Budget's (OMB's) approval for an existing information collection titled "Home Mortgage Disclosure Act (Regulation C)" approved under OMB Control Number 3170–0008.

**DATES:** Written comments are encouraged and must be received on or before February 9, 2026 to be assured of consideration.

**ADDRESSES:** You may submit comments, identified by the title of the information collection, OMB Control Number (see below), and docket number (see above), by any of the following methods:

- *Federal eRulemaking Portal:* <http://www.regulations.gov>. Follow the instructions for submitting comments.

- *Email:* [CFPB\\_PRA@cfpb.gov](mailto:CFPB_PRA@cfpb.gov). Include Docket No. CFPB–2025–0049 in the subject line of the email.

- *Mail/Hand Delivery/Courier:* Comment Intake, Consumer Financial Protection Bureau (Attention: PRA Office), 1700 G Street NW, Washington, DC 20552. Because paper mail in the Washington, DC area and at the CFPB is subject to delay, commenters are encouraged to submit comments electronically.

Please note that comments submitted after the comment period will not be accepted. In general, all comments received will become public records, including any personal information provided. Sensitive personal information, such as account numbers or Social Security numbers, should not be included.

**FOR FURTHER INFORMATION CONTACT:** Requests for additional information should be directed to Anthony May, PRA Officer, at (202) 435–7278, or email: [CFPB\\_PRA@cfpb.gov](mailto:CFPB_PRA@cfpb.gov). If you require this document in an alternative electronic format, please contact [CFPB\\_Accessibility@cfpb.gov](mailto:CFPB_Accessibility@cfpb.gov). Please do not submit comments to these email boxes.

#### SUPPLEMENTARY INFORMATION:

*Title of Collection:* Home Mortgage Disclosure Act (Regulation C).

*OMB Control Number:* 3170–0008.

*Type of Review:* Extension of an information collection.

*Affected Public:* Individuals and households.

*Estimated Number of Respondents:* 136.

*Estimated Total Annual Burden Hours:* 1,510,960.

*Abstract:* The Home Mortgage Disclosure Act (HMDA) requires certain